8-K ·Filed Apr 7, 2026
8-K material event: Items 4.01
Actionable Insight • Neutral
Monitor for any follow-up filings or delays in future financial reporting that could signal underlying issues; auditor changes can sometimes precede restatements or increased scrutiny.
Final — all horizons settled through T+60d ⚠ clustered
ANIP ▲ +8.88% at T+60d
NEUTRAL call ✓ call won +8.88% · α vs SPY -1.57% · entry $79.01 → $86.03
T+1d
+1.43%
call +1.43% · α +0.86%
$80.14
settled 6mo ago
T+5d
-3.20%
call -3.20% · α -6.72%
$76.48
settled 6mo ago
T+20d
+7.11%
call +7.11% · α -1.43%
$84.63
settled 5mo ago
T+60d
+8.88%
call +8.88% · α -1.57%
$86.03
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
ANI Pharmaceuticals dismissed EisnerAmper as its auditor and appointed Ernst & Young effective April 1, 2026. The change was approved by the Audit Committee, with no reported disagreements or reportable events with the former auditor.
Key Facts
- ANI Pharmaceuticals dismissed EisnerAmper LLP as its independent registered public accounting firm effective April 1, 2026.
- Ernst & Young LLP was appointed as the new auditor effective the same date, with approval from the Audit Committee.
- EisnerAmper confirmed in a letter that it agrees with the company's statements and has no disagreements.
- No disagreements or reportable events were disclosed with EisnerAmper during their tenure.
- The company did not consult Ernst & Young on any matters prior to their appointment.
Financial Impact
No direct financial impact disclosed; auditor change without identified accounting issues.
audit qualitygovernance perception
Risk Factors
- Potential perception of reduced audit quality if Ernst & Young identifies material weaknesses in future filings.
- Increased investor skepticism due to auditor turnover, especially in the pharmaceutical sector with complex accounting.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000034 |
| Document: anip-ex161.htm | 0001023024-26-000034 |
| Document: 0001023024-26-000034-index-headers.html | 0001023024-26-000034 |
| Document: 0001023024-26-000034-index.html | 0001023024-26-000034 |
| Document: 0001023024-26-000034.txt | 0001023024-26-000034 |
21 reports for ANIP
43% Hit rate best @ T+60▲ +8.88%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $72.11 $77.91 | ▲ +8.04% | ▲ +7.23% | $71.97 (−0.19%) |
Sep 1, 2026 4w ago | Insider Cluster | $73.06 $71.46 | ▼ −2.19% | ▼ −1.23% | $71.97 (−1.49%) |
Aug 24, 2026 5w ago | 8-K | $74.17 $73.25 | ▼ −1.24% | ▼ −1.71% | $71.97 (−2.97%) |
Aug 13, 2026 7w ago | Insider Cluster | $74.77 $77.32 | ▲ +3.41% | ▲ +5.37% | $71.97 (−3.74%) |
Aug 7, 2026 8w ago | 8-K | $78.25 $76.54 | ▼ −2.19% | ▼ −2.58% | $71.97 (−8.03%) |
Jul 16, 2026 11w ago | Court Ruling | $81.92 $78.53 | ▼ −4.14% | ▼ −2.47% | $71.97 (−12.15%) |
Jul 13, 2026 11w ago | Press Release | $81.08 $79.20 | ▼ −2.32% | ▼ −1.53% | $71.97 (−11.24%) |
Jun 15, 2026 15w ago | Insider Cluster | $83.00 $82.94 | ▼ −0.07% | ▲ +2.16% | $71.97 (−13.29%) |
Jun 11, 2026 16w ago | Insider Cluster | $81.65 $80.52 | ▼ −1.38% | ▼ −1.82% | $71.97 (−11.86%) |
May 21, 2026 19w ago | 8-K | $82.72 $76.71 | ▼ −7.27% | ▼ −8.92% | $71.97 (−13.00%) |
Showing 10 of 21
US Market Status
Market Open — Closes in 2h 19m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access